Arcutis Biotherapeutics, Inc. Income Statement
ARQT / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Arcutis Biotherapeutics, Inc. reported $376M in revenue and $16M in net loss for FY2025. Revenue has grown at a 367.3% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | - | - | - | - |
| Cost of Revenue | $36.7M | $19.1M | $5.0M | $754.0K | $0 | - | - | - |
| SG&A Expense | $274.6M | $229.4M | $185.1M | $122.1M | $61.0M | $21.3M | $6.6M | $1.8M |
| R&D Expense | $77.1M | $76.4M | $110.6M | $182.4M | $145.6M | $115.3M | $36.5M | $17.9M |
| Operating Income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M | -$136.6M | -$43.1M | -$19.7M |
| Interest Expense | - | - | $29.7M | $15.7M | $0 | $0 | - | - |
| Income Tax | $1.2M | $647.0K | $3.1M | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M | -$135.7M | -$42.0M | -$19.3M |
| EPS (Basic) | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | - |
| EPS (Diluted) | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | - |
| Shares Outstanding | 123.3M | 117.8M | 69.3M | 55.0M | 49.4M | 35.7M | 1.8M | 1.2M |
| Operating Margin | -3.3% | -65.3% | - | - | - | - | - | - |
| Profit Margin | -4.3% | -71.3% | - | - | - | - | - | - |